Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction.
作者信息
Biondi-Zoccai Giuseppe, Galli Mattia, Booz George W
机构信息
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy; and.
出版信息
J Cardiovasc Pharmacol. 2024 Dec 1;84(6):551-552. doi: 10.1097/FJC.0000000000001636.
Abstract
摘要
相似文献
1
Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction.非奈利酮对射血分数保留的心力衰竭患者有益。
J Cardiovasc Pharmacol. 2024 Dec 1;84(6):551-552. doi: 10.1097/FJC.0000000000001636.
2
Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.非奈利酮与轻度射血分数降低或保留的门诊恶化型心力衰竭：FINEARTS-HF随机临床试验的二次分析
JAMA Cardiol. 2025 Feb 26;10(4):370-8. doi: 10.1001/jamacardio.2025.0016.
3
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial.非奈利酮与心力衰竭患者的肾脏结局：FINEARTS-HF试验
J Am Coll Cardiol. 2025 Jan 21;85(2):159-168. doi: 10.1016/j.jacc.2024.10.091. Epub 2024 Oct 25.
4
Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the Management of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.非奈利酮对盐皮质激素受体的拮抗作用：射血分数轻度降低或保留的心力衰竭患者管理的新时代。
Am J Cardiovasc Drugs. 2025 Mar 7. doi: 10.1007/s40256-025-00723-2.
5
[Mineralocorticoid receptor antagonists in heart failure with preserved/mildly reduced ejection fraction: from TOPCAT to FINEARTS-HF].[射血分数保留/轻度降低的心力衰竭中的盐皮质激素受体拮抗剂：从TOPCAT研究到FINEARTS-HF研究]
G Ital Cardiol (Rome). 2025 Jan;26(1):38-49. doi: 10.1714/4394.43958.
6
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.非甾体类盐皮质激素受体拮抗剂非奈利酮联合或不联合SGLT2抑制剂用于心力衰竭的疗效
Circulation. 2025 Jan 14;151(2):149-158. doi: 10.1161/CIRCULATIONAHA.124.072055. Epub 2024 Sep 28.
7
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.非奈利酮治疗射血分数轻度降低或保留的心力衰竭。
N Engl J Med. 2024 Oct 24;391(16):1475-1485. doi: 10.1056/NEJMoa2407107. Epub 2024 Sep 1.
8
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.非奈利酮、肥胖与射血分数轻度降低/保留的心力衰竭：FINEARTS-HF的预设分析
J Am Coll Cardiol. 2025 Jan 21;85(2):140-155. doi: 10.1016/j.jacc.2024.10.111. Epub 2024 Dec 10.
9
The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment.非奈利酮在慢性肾脏病合并2型糖尿病综合管理中的作用以及对心力衰竭预防和治疗的意义。
Heart Fail Rev. 2025 May 31. doi: 10.1007/s10741-025-10520-3.
10
Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial.根据心力衰竭中的衰弱情况分析非奈利酮：FINEARTS-HF随机临床试验的预设分析
JAMA Cardiol. 2025 Jun 18. doi: 10.1001/jamacardio.2025.1775.
引用本文的文献
1
Finerenone and semaglutide: Role in heart failure with reduced ejection fraction.非奈利酮和司美格鲁肽：在射血分数降低的心力衰竭中的作用。
World J Cardiol. 2025 May 26;17(5):105822. doi: 10.4330/wjc.v17.i5.105822.
本文引用的文献
1
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.司美格鲁肽对比安慰剂在射血分数轻度降低或保留的心衰患者中的疗效：SELECT、FLOW、STEP-HFpEF 和 STEP-HFpEF DM 随机试验的汇总分析。
Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30.
2
Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment.肾移植后移植后糖尿病的管理：治疗挑战与进展
Pharmaceuticals (Basel). 2024 Jul 26;17(8):987. doi: 10.3390/ph17080987.
3
State of the art on angiotensin-neprilysin inhibitors.血管紧张素-中性内肽酶抑制剂的最新进展
Minerva Cardiol Angiol. 2024 Jun 5. doi: 10.23736/S2724-5683.24.06500-1.
4
2024 update in heart failure.2024年心力衰竭治疗进展
ESC Heart Fail. 2025 Feb;12(1):8-42. doi: 10.1002/ehf2.14857. Epub 2024 May 28.
5
Comparison of clinical characteristics and prognostic factors in patients with heart failure with preserved ejection fraction with and without renal dysfunction.射血分数保留的心力衰竭患者伴和不伴肾功能不全时的临床特征及预后因素比较
Minerva Cardiol Angiol. 2024 Dec;72(6):615-624. doi: 10.23736/S2724-5683.24.06510-4. Epub 2024 May 23.
6
Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists.醛固酮受体过度激活：用非甾体类醛固酮受体拮抗剂靶向全身影响。
Diabetologia. 2024 Feb;67(2):246-262. doi: 10.1007/s00125-023-06031-1. Epub 2023 Dec 21.
7
Efficacy and Safety of a Polypill to Reduce Cardiovascular Events: A Review of Clinical Trials.复方药降低心血管事件的疗效和安全性：临床试验综述。
J Cardiovasc Pharmacol. 2024 Jan 1;83(1):8-15. doi: 10.1097/FJC.0000000000001508.
8
Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors.非奈利酮通过调节促炎和成骨因子预防 1 型糖尿病模型的肾脏和心血管损伤进展。
Biomed Pharmacother. 2023 Dec;168:115661. doi: 10.1016/j.biopha.2023.115661. Epub 2023 Oct 11.
9
Involvement of pyroptosis pathway in epicardial adipose tissue - myocardium axis in experimental heart failure with preserved ejection fraction.射血分数保留的实验性心力衰竭中心外膜脂肪组织-心肌轴中焦亡途径的参与
Biochem Biophys Res Commun. 2022 Dec 25;636(Pt 2):62-70. doi: 10.1016/j.bbrc.2022.10.109. Epub 2022 Nov 2.
10
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
Zotero 插件